A program for early detection and prevention of pancreatic cancer
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
H. Lee Moffitt Cancer Center and Research Institute · NCT05692596
This study is testing a new program to find and prevent pancreatic cancer early in people who have pancreatic cysts or a family history of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute (other) |
| Locations | 1 site (Tampa, Florida) |
| Trial ID | NCT05692596 on ClinicalTrials.gov |
What this trial studies
The Pancreas Interception Center aims to develop effective clinical strategies for the early detection, prevention, and treatment of pancreatic ductal adenocarcinoma (PDAC) and related conditions. This observational study will collect data from patients at the Moffitt Cancer Center who present with pancreatic cysts or genetic predispositions to PDAC. By identifying risk factors and monitoring patients, the program seeks to reduce the burden of pancreatic cancer and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include patients aged 18 and older at Moffitt Cancer Center with pancreatic cysts or genetic predispositions to PDAC.
Not a fit: Patients without any risk factors for pancreatic cancer or those not affiliated with Moffitt Cancer Center may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could lead to earlier detection and better prevention strategies for pancreatic cancer, ultimately saving lives.
How similar studies have performed: Other studies focusing on early detection and prevention of pancreatic cancer have shown promise, indicating that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC) * Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC. * Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.
Where this trial is running
Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida, United States (RECRUITING)
Study contacts
- Principal investigator: Shaffer Mok, MD, MBS — Moffitt Cancer Center
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Lynch Syndrome